Biotechnology

Akari Therap

Akari Therapeutics and WuXi XDC Collaborate on AKTX-101 GMP Production

Akari Therap released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1959 (forecast USD -0.12)

Akari Therap released FY2025 9 Months Earnings on November 13 (EST) with actual revenue of USD 0 and EPS of USD -0.3918

Akari Therapeutics Submits Two Patent Applications to USPTO

Jason McCarthy Reiterates Buy Rating on Akari Therapeutics

Akari Therap released FY2025 Q2 earnings on August 13, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.0602 (forecast USD -0.11)

Akari Therap released FY2025 Semi-Annual Earnings on August 13 (EST), with actual revenue of USD 0 and EPS of USD -0.1905

Akari Therapeutics CEO Acquires Company Stocks

Akari Therapeutics Obtains PH1 Antibody-Drug Conjugate Patent in India

Akari Therapeutics Releases Video Introducing New Oncology Business Development Leader

Akari Therap released FY2025 Q1 earnings on May 14 EST, actual revenue USD 0, actual EPS USD -0.1357

Akari Therapeutics Sees Sufficient Cash to End September 2025

Akari Therap released FY2024 earnings on April 15 (EST), actual revenue USD 0 (forecast USD --), actual EPS USD -1.6569 (forecast USD -3.4)

Akari Therap released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD --), actual EPS USD -0.1943 (forecast USD -1)

Akari Therap released FY2024 Q3 earnings on November 19 (EST), actual revenue 0 USD, actual EPS -0.2374 USD (forecast EPS -0.6 USD)

Akari Therap released FY2024 Cumulative 3Q Earnings on November 19 (EST), with actual revenue of 0 and EPS of -1.8673

Akari Therap released FY2023 Q4 earnings on March 29 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9407 (forecast USD -1)

Intelligent Bio Solutions

Anghami

UTime

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

FG MERGER II CORP COM USD0.0001 11/02/2030 (SUBS/RTS)

ESH Acquisition

INFLECTION POINT ACQUISITION CORP V COM USD0.0001 CL A (SUB/RIGHST)

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Datavault AI

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Akari Therap(AKTX.US)